Dentsply Sirona Falls Over 4% Following Q1 Results - Read Why

Zinger Key Points
  • Dentsply Sirona's Q1 revenue misses at $953M, down 2.6% YoY; adjusted EPS meets expectations at 42 cents.
  • Dentsply Sirona says FY24 adjusted EPS and organic sales are trending towards the low-end of outlook ranges.

Dentsply Sirona Inc. XRAY shares are trading lower on Thursday after reporting first-quarter results.

The company reported adjusted earnings per share of 42 cents, in line with the street view. 

Quarterly revenues of $953 million missed the street view of $969.136 million. Sales fell 2.6% year over year.

Segment wise, Connected Technology Solutions fell 6.9%, Essential Dental Solutions fell 5.9%, Orthodontic and Implant Solutions gained 4.4%, and Wellspect Healthcare rose 5.4%. 

Quarterly gross profit of $506 million fell 2.5% year over year. Gross margin remained flat at 53.1%.

The company adjusted EBITDA margin of 16.8%, slightly higher than 16.5% a year ago. Quarterly Adjusted EBITDA fell 1.1% to $160 million.

“We did see some bright spots in the business in Q1, with over 50% growth in China, double-digit growth in our global aligners business and U.S. CAD/CAM, and mid-single digit growth in Wellspect Healthcare,” said Simon Campion, President and Chief Executive Officer.

Operating cash flow in the first quarter of 2024 was $25 million, compared to ($21) million in the prior year, primarily as a result of a lower inventory build and improved cash collections. 

The company had $291 million of cash and cash equivalents as of March-end.

Outlook: The company maintained its 2024 outlook for organic sales growth in the range of flat to up 1.5%, and adjusted EPS in the range of $2.00 to $2.10 (street view: $2.06). 

Based on its latest view of the macroeconomic environment, the company believes adjusted EPS and organic sales are trending towards the low-end of both ranges. 

The company revised its anticipated reported sales to a new range of $3.91 billion to $3.97 billion due to an additional estimated foreign currency translation headwind of $50 million (street view: $3.99 billion). 

Price Action: XRAY shares are trading lower by 4.31% to $28.88 at last check Thursday.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesNewsGuidanceMarketsMoversGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!